GSK-A1

GSK-A1 is a selective type III phosphatidylinositol 4-kinase PI4KA (PI4KIIIα) inhibitor with a pIC50 of 8.5-9.8. GSK-A1 inhibits PtdIns (4,5) P2 resynthesis with an IC50 of about 3 nM. GSK-A1 potently decreases the levels of PtdIns (4) P with a negligible effect on PtdIns (4,5) P2. GSK-A1 has the potential for anti-hepatitis C virus (HCV) research[1].

Product Specifications

CAS Number

[1416334-69-4]

UNSPSC

12352005

Target

HCV; PI4K

Type

Reference compound

Related Pathways

Anti-infection; PI3K/Akt/mTOR

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/gsk-a1.html

Purity

99.04

Solubility

DMSO : ≥ 2 mg/mL|H2O : < 0.1 mg/mL (ultrasonic)

Smiles

O=S(C1=CC(C2=CC=C3N=C(N)N(C4=CC=C(N5CCOCC5)C=C4)C3=C2)=CN=C1OC)(NC6=CC=CC=C6F)=O

Molecular Formula

C29H27FN6O4S

Molecular Weight

574.63

References & Citations

[1]Naveen Bojjireddy, et al. Pharmacological and genetic targeting of the PI4KA enzyme reveals its important role in maintaining plasma membrane phosphatidylinositol 4-phosphate and phosphatidylinositol 4,5-bisphosphate levels. J Biol Chem. 2014 Feb 28;289 (9) :6120-32.|[2]Smulders L, et al. Phosphatidylinositol Monophosphates Regulate the Membrane Localization of HSPA1A, a Stress-Inducible 70-kDa Heat Shock Protein. Biomolecules. 2022 Jun 20;12 (6) :856. |[3]Jiang X, et al. Targeting PI4KA sensitizes refractory leukemia to chemotherapy by modulating the ERK/AMPK/OXPHOS axis. Theranostics. 2022 Oct 3;12 (16) :6972-6988. |[4]Li FL, et al. Hippo pathway regulation by phosphatidylinositol transfer protein and phosphoinositides. Nat Chem Biol. 2022 Oct;18 (10) :1076-1086.